Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.
Press releases published on May 13, 2025

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway
IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 …

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline …

Reviva to Participate in the A.G.P. Healthcare Company Showcase
CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central …

Advanced Technology International Acquires Carrot
SUMMERVILLE, S.C., May 13, 2025 (GLOBE NEWSWIRE) -- We are excited to announce that effective March 31, 2025, Advanced Technology International (ATI), a South Carolina based 501(c)3 public service nonprofit, acquired the assets of The Common Pool, LLC, dba …

red violet to Present at the 25th Annual B. Riley Securities Investor Conference
BOCA RATON, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced that it will present at the 25th Annual B. Riley Securities Investor Conference being held May 21-22 …

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend …

Reflect Scientific Secures Patents for Data Center Cooling with Cryogenic Innovation
OREM, Utah, May 13, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leader in cryogenic technology, today announced a U.S. Patent for its innovative system to cool computer rooms using cryogenic methods. This development addresses the …

Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™
The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second …

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials
Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investors Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in patients with acute myeloid leukemia (AML) …

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …

Acronis Ecosystem Reaches 300 Technology Integrations, Drives New Opportunities for MSPs and ISVs
SHAFFHAUSEN, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- Acronis, a global leader in cybersecurity and data protection, today announces a significant milestone in the Acronis Technology Ecosystem, which now includes nearly 300 integrations, reinforcing …

NEVGOLD ADDS MORE SIGNIFICANT OXIDE GOLD-ANTIMONY RESULTS: 2.19 G/T AUEQ OVER 64.0 METERS (0.72 G/T AU AND 0.33% ANTIMONY), INCLUDING 4.17 G/T AUEQ OVER 24.1 METERS (1.47 G/T AU AND 0.60% ANTIMONY), AND ALSO INCLUDING 10.86 G/T AUEQ OVER 4.50 METERS…
Vancouver, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that it has discovered further significant oxide gold-antimony (“Antimony”, “Sb”) …

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and …

Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies
In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs) In 15% or …

Intuitive Machines Reports First Quarter 2025 Financial Results
HOUSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), a leading space technology and infrastructure services company, today announced its financial results for the first quarter ended …

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“ …

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic …

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter from sales and collaborative research agreement – - …

Atomic Minerals Announces Share Exchange Agreement to Acquire Quebec Mineral Claims
Vancouver, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Atomic Minerals Corporation ("Atomic Minerals" or the "Company") (TSX Venture: ATOM) is pleased to announce that it has entered into a share exchange agreement (the “Agreement”) with the …